Off-topic for aiqbench
This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Wired1 min read
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
Read the full article at WiredRelated coverage
People might start believing in radical life extension soon
LessWrong · Jul 20, 2026
Links #5: 2026/07
LessWrong · Jul 31, 2026
AI Products
[AINews] not much happened today
Latent Space · Oct 3, 2026
AI Products
[AINews] Meta Muse Wonder & Wonder Full: MSL’s Claude 5.5-tier Frontier Model
Latent Space · Oct 13, 2026